Tag Archives: travel

Navigating JPM Week: A Guide to RESI’s 2026 Event Lineup 

18 Nov

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

As the life science world converges on San Francisco for J.P. Morgan Healthcare Week in January 2026, the RESI Conference plays a central role, and its website’s dedicated “JPM Week Events” page is an essential resource for attendees and stakeholders alike. Here’s a breakdown of what the site offers and why it’s such a valuable hub.

What Is the JPM Week Events Page?

The RESI “JPM Week Events” page is essentially a curated calendar and guide, maintained by Life Science Nation. It compiles an exhaustive list of life science–oriented events happening in parallel with JPM Healthcare Week, from early morning breakfasts to high-level receptions and symposiums.

It’s not just a list; it’s a strategic tool for entrepreneurs, investors, and corporates to plan how to maximize their time during one of the most frenetic weeks in biotech and healthcare investments.

What’s on the Agenda: Highlights from the 2026 Schedule

Here is some standout events listed for January 2026 on RESI’s page:

January 10–11:

  • San Francisco CEO | Longwood Healthcare Leaders Forum — A full-day leadership forum at the Four Seasons.
  • 9th Annual Neuroscience Innovation Forum — Focused on business development, licensing, and investment, held at the Marines’ Memorial Club.
  • PwC Executive Women’s Event — A networking event aimed at women leaders in healthcare.
  • Yafo Capital ACCESS ASIA BD Forum — A cross-border business development forum in San Francisco.

January 12:

  • RESI JPM 2026 Conference at the San Francisco Marriott Marquis.
  • AcuityMD Sunrise Partnering Breakfast — An early morning session for high-value partnering.
  • AdvaMed Member Meeting Space & Receptions — Dedicated space for AdvaMed members.
  • Incubate & DLA Piper: Innovation at a Crossroads — A policy-focused discussion on biopharma strategy in a changing global landscape.
  • Lifeblood & Goodwin MedTech CEO-only Forum — A specialized gathering for medtech CEOs.
  • MassBio Meeting Space & Receptions — Hosted by MassBio at the Parc 55 Hotel.
  • QNova LifeSciences 12th Annual Partnering Forum — A major partnering event in the Hilton Union Square.
  • PMI Biotech Reception — A dinner reception at InterContinental Mark Hopkins.
  • Aquillius Pitch Showcase — A pitching event for life sciences companies.
  • Biovia Event: Clusters of Excellence — A forum on European life science clusters and global success.
  • T2Bmeet @ JPM — A streamlined meeting event to facilitate business development and partnering.
  • Scale Biosciences JPM Happy Hour — Evening social for dealmakers.
  • STAT @ JPM26 Live — A live event by STAT News.
  • Reed Smith Reception — At the Museum of the African Diaspora.
  • Deloitte Reception — A networking evening hosted by Deloitte.

January 13:

  • Continuation of RESI JPM 2026.
  • Fierce JPM Week — A track that runs throughout JPM Week, focused on dealmaking and thought leadership.
  • Biocom California Events — Receptions, meeting space, and more at Omni San Francisco.
  • KoreaBIO / BioCentury / Sidley Austin IR Forum — Global investor relations forum.
  • LaunchBio & Inspira Innovators Social Hour — A more informal social event for early-stage founders.
  • Katten’s Diptyque Client Reception — A luxury experience for select invitees.
  • Dartmouth Offsite — Hosted at the Beacon Grand Hotel.
  • Bits in Bio Reception — For emerging biotech companies and leaders.

January 14–15:

  • Multiple networking breakfasts, partnering forums, and receptions.
  • HCPEA Women’s Mentor/Mentee Networking Breakfast on January 14.
  • 2026 Stanford Alumni in Healthcare Networking Mixer — A Stanford alumni focused event.
  • CTIP Innovator Showcase (Jan 15) — For pediatric technology innovators.
  • MBC BioLabs: Meet the Founders — Founders’ networking at a biotech incubator.
  • Toplink Conference @ JPM — A full-day conference on tech + life science.
  • And more receptions, including PCI Pharma Services, California Israel Chamber of Commerce Israel Lounge, and Destination Medical Center Discovery Exchange.

Why This Page Matters

  1. Comprehensive Planning Tool: For anyone attending JPM Week — whether founders, investors, BD execs, or scientists — having a central, curated list of relevant life science events is invaluable. Rather than navigating a sea of scattered invitations, the RESI page brings together a clean, structured schedule.
  1. Partnership Optimization: Many of the events listed are tailored for dealmaking — breakfasts, partnering forums, and pitch showcases. This makes it easier for startups to schedule and maximize high-impact interactions.
  1. Community Spotlight: The page isn’t only about formal conferences; it also highlights social events, networking mixers, and sector-specific receptions (e.g., women in healthcare, neuroscience, medtech). This helps attendees connect on both professional and personal levels.

The RESI “JPM Week Events” page is more than just a listing: it’s a strategic roadmap for navigating one of the busiest and most important weeks in healthcare investing. By consolidating diverse events, boardroom policy talks to rooftop cocktail receptions; it empowers life science professionals to plan smarter, connect deeper, and maximize their time.

For anyone participating in RESI JPM 2026, bookmarking this page is one of the first steps to making the most of the week.

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , , , ,

Make Your Mark at RESI JPM with the New Company Presentation Track 

12 Nov

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Showcase your brand, services, and expertise to a global life science audience 

Life Science Nation (LSN) is introducing a new opportunity at RESI JPM 2026, the Company Presentation Track, designed for service providers, established companies, and later-stage ventures seeking to elevate their brand visibility and connect with decision-makers across the global life science ecosystem. 

Taking place January 12-13, 2026, at the Marriott Marquis in San Francisco, RESI JPM will also feature three days of virtual partnering on January 14, 19–20. RESI JPM will bring together hundreds of early-stage life science and healthcare companies and over 500 global investors for two full days of partnering, investor panels, and networking. 

The new Company Presentation Track offers organizations a unique platform to deliver a 15-minute presentation highlighting their business, market positioning, and value proposition. Unlike the Innovator’s Pitch Challenge, which focuses on fundraising and investor feedback for early-stage startups, these company presentations are designed for firms looking to expand their visibility, attract new clients, and strengthen their strategic partnerships. 

Participants in this track will have the opportunity to: 

  • Present their company, products, and services to an engaged global audience. 
  • Build brand recognition among investors, partners, and industry peers. 
  • Demonstrate thought leadership and industry expertise in a highly visible format. 

This new feature adds to RESI’s robust mix of investor panels, workshops, partnering meetings, and exhibition opportunities, making it a comprehensive platform for business development and partnership-building across the life science sector. 

Make your mark at RESI JPM. Share your story, elevate your brand, and connect with investors, innovators, and service providers driving the future of healthcare innovation. 

To apply, select Company Presentation during your RESI JPM registration or contact the RESI team at RESI@lifesciencenation.com for more information. 

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , ,

RESI London 2025: Dec 4! See feedback from previous attendees about the UK’s biggest investment conference!

21 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

RESI London 2025 will be the second year of the UK’s biggest life science investor conference. We expect 250 investors, ready to finance your company. The RESI partnering system allows you to schedule face to face meetings with each investor. See what last year’s attendees are saying!

Testimonials

“RESI London was an extremely productive experience for my company, and the partnering system was so easy to use.”

– Nick Sireau, CEO, Serenatis Bio

“RESI is the go-to meeting for biotech CEOs’ seeking early stage capital. They have built an early stage platform educating founders and bringing capital to them. They are the only people serving this under loved sub sector with such passion.”

– Sunil Shah, CEO, O2h Ventures & Co-founder, O2h Group

“Attending RESI London for the first time was a refreshing and highly positive experience. The event exceeded my expectations in several ways. The atmosphere was welcoming and collaborative, which created a conducive environment for meaningful interactions. What stood out most was the exposure to a unique group of investors—those with a specific interest in early-stage, cutting-edge technologies. These are exactly the type of investors we aim to connect with at Rinri, so the conference provided an excellent platform to engage with individuals who understand the risks and rewards of innovative science-driven ventures.”

– Simon Chandler, CEO, Rinri Therapeutics

“My session was punctual and well-organized. The jury members were thoughtfully selected and provided insightful, constructive feedback that was highly valuable.”

– Christine Ruckenbauer, CBO, RIANA Therapeutics

“I highly value RESI and am grateful for the opportunity both to contribute as a pitch judge, company scouting and the networking opportunities. You have a dynamic network with easy, friendly, professional access. Thanks for all you are doing for the life science and tech development sector.”

– Jill Sorensen, MTEC (Investor)

“As One Nucleus seeks to enable our members to engage with the widest possible investor pool, partnering with RESI London creates a unique opportunity to bring our members into contact with new global early-stage investors to complement the known local investors they meet at all other early-stage pitching events in the UK.”

– Tony Jones, CEO, One Nucleus

“We started this as a grassroots meeting with One Nucleus, and it has been extremely gratifying and rewarding to see our international investors attending because the UK, we know, has some great science that needs to get to the global stage. We are expecting 250+ investors.”

– Dennis Ford, CEO, Life Science Nation

Register RESI London by Friday, October 24 to save £200 on early bird rates!

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , , , , , , , , , , , , , , , ,

Make the Most of JPM Week with Sunday Partnering at the Marriott Marquis 

21 Oct

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

JPM week is coming fast, and the best opportunities go to those who plan early. If you still haven’t secured a venue or partnering space, Life Science Nation (LSN) has your solution. As the host of RESI JPM, LSN is opening Sunday partnering at the Marriott Marquis, giving attendees an extra day to meet face-to-face with fellow RESI participants or connect informally outside the partnering system before the main event begins.

Sunday partnering provides a head start on the biggest week in healthcare investment, whether you’re scheduling investor meetings, gathering your team, or hosting your own private event. The Marriott Marquis is at the center of the JPM ecosystem, making it the perfect base for receptions, showcases, and partnering tables throughout the week.

If you represent a membership organization, this is your chance to give your members valuable exposure and a convenient home base in San Francisco—without the steep prices other hotels are charging for table rentals. And for product or service providers, sponsoring or exhibiting at RESI remains the most direct and cost-effective way to meet early-stage innovators. Unlike other partnering events, RESI’s community welcomes vendor meetings, and our partnering stats show that clearly.

Life Science Nation is here to help you make the most of the biggest week of the year. Whether you’re planning a private reception, setting up a partnering table, or joining RESI as an exhibitor, our team can help you build visibility, secure meetings, and connect with the early-stage life science community that gathers at JPM each January.

Register RESI JPM by Friday, October 24 to save $600 on early bird rates!

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , ,

Will PubMed be Shutdown? 

15 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

Many in the life sciences research community were spooked when PubMed went down temporarily in March after the Trump administration cut $4 billion in “indirect costs” that supported medical research. More recently, an ominous message appeared on PubMed: “Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed…” Many who use PubMed but not other government websites were probably panicked by this, but a quick look at clinicaltrials.gov, NIH Reporter and even NIH’s main site reveals the same message, while different versions of this message appear on the websites of HHS, CMS, etc.

Still, various EU governments have been quietly preparing for a PubMed shutdown by ensuring they will have a PubMed-alternative just in case. Of course, let’s be real: while they may be able to serve the existing content in PubMed, they will not be able to suddenly support the thousands of additional abstracts and articles added each day, along with MeSH tagging, journal selection, XML/JSON feeds, and other critical functions PubMed provides.

While PubMed is critical to nearly every life science researcher, even those with access to Web of Science, Embase, etc., it is especially critical to early-stage life science companies and investors. For basic research, competitive intelligence, due diligence and more, PubMed is indispensable for those without access to paid literature databases. PubMed is also an important source for pipeline database providers that investors and pharma use to find assets and perform CI.

The US government, for decades, has supplied a critical and reliable literature resource for worldwide audiences, both professional and non-professional alike. With the addition of the first and best clinical trial registry in 2000, continued funding for this resource is paramount for global biomedical research.

Tags: , , , , , , , , , , , , , , , , , , ,

From RESI Boston to Global Growth: Bilix on Winning the Innovator’s Pitch Challenge

15 Oct
Myung Kim
   CaitiCaitlin Dolegowski

Bilix, recognized as a top Innovator’s Pitch Challenge winner at RESI Boston this past September, is making waves in the biotech space with its innovative multi-modality approach to inflammatory and autoimmune diseases. In this interview, Myung Kim, Founder and CEO, shares how participating in RESI Boston helped the company connect with key investors, refine its strategy, and advance its clinical milestones.

Hear firsthand how Bilix is driving progress in complex disease treatment and discover how your company can join the next generation of innovators pitching at RESI London and RESI JPM. Applications are now open.

Apply to Pitch at RESI London Apply to Pitch at RESI JPM

Tags: , , , , , , , , , , , , , , , , , , , , ,

How 100% Pharma Tariffs Could Ripple Through Early-Stage Biotech Investment 

7 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

We have all heard about the recent 100% pharma tariff announcement, applicable mainly to manufacturers or marketed drugs unless they are in the process of building manufacturing facilities in the US. We know that early stage biotechs are generally not counting on investment to take them through manufacturing, for which they will seek a pharma partner. Nevertheless, these tariffs may still have an effect on early-stage biotech investments. Investment in early-stage (seed, Series A/B) biotech is likely to face increased headwinds under a 100 % pharmaceutical tariff regime. The tariff risk exacerbates existing structural challenges in biotech investing.

Overall Expected Effect (Short to Medium Term) 

  • Slower fundraising pace 
    The number of deals may decline, particularly in the earlier stages. Biotech investors will likely become more selective, preferring de-risked assets, strong data, or compelling platforms with clear strategies to mitigate tariff exposure.
  • Higher effective cost of capital 
    Investors will demand more upside or stricter protections (e.g. liquidation preferences, anti-dilution) to compensate for the added risk.
  • Greater emphasis on capital efficiency / leaner burn models 
    Startups may need to conserve cash more, focus earlier on key inflection points, outsource less, and plan fallback strategies for supply chain risk.
  • Longer timelines / delayed exits 
    Because of the risk, uncertainty, and possible delays, the time to IPO, acquisition, or commercialization may stretch, further compressing IRR for investors.
  • Capital flow shift toward infrastructure and enabling technologies 
    Some portion of venture capital may redirect toward bioprocessing, domestic manufacturing, synthetic biology for local API production, supply-chain tools — companies that can help others evade tariff impact.
  • Public market investment in pharma may slow, leading to less IPOs 
    The tariffs could serve to further erode the attractiveness of the biopharma sector for public market investors, reducing the room for IPOs, and pressuring investment taking place more upstream.

In summary, while the recent 100% pharma tariffs certainly don’t have a direct effect on early-stage biotech investing, their dampening effects will nonetheless be felt.

Tags: , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →